These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 38271367)

  • 1. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
    Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
    Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
    Abelman RO; Medford A; Spring L; Bardia A
    Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates in HER2-positive breast cancer.
    Li L; Zhang D; Liu B; Lv D; Zhai J; Guan X; Yi Z; Ma F
    Chin Med J (Engl); 2021 Dec; 135(3):261-267. PubMed ID: 34935688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment.
    Gao X; Bu T; Wang W; Xu Y
    Breast Cancer (Dove Med Press); 2024; 16():621-630. PubMed ID: 39310781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low.
    Fan P; Xu K
    Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188849. PubMed ID: 36502928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
    Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J
    Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
    Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
    Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
    Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
    Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
    Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
    Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy.
    Jeong JH; Kim SB
    Breast; 2022 Dec; 66():199-203. PubMed ID: 36327625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
    Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
    Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer.
    Abelman RO; Keenan JC; Ryan PK; Spring LM; Bardia A
    Hematol Oncol Clin North Am; 2023 Feb; 37(1):151-167. PubMed ID: 36435607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.